Skip to content
  • 6,949 federal solicitations are open right now. How many of them are yours?
  • New solicitations are posted every day. The ones you never saw are the ones you cannot win.
  • Stop checking SAM.gov every morning. Let the contracts that fit your business come to you.
  • Tell Abierto what you sell in one sentence. AI reads every open solicitation for you.
  • Deadlines are short. Hear about a solicitation the day it is posted, not the week it closes.
  • Amendments move deadlines. Watch a solicitation and Abierto tells you when it changes.
  • See which contracts in your field are about to end, and who holds them today.
  • Plans from $39 a month. See your matches before you pay.
See plans
AbiertoGet started
Menu

Sources sought

Detection and characterization of influenza viruses

GPO416801CDC

Centers for Disease Control and Prevention, CDC Office of Acquisition Services. In-Vitro Diagnostic Substance Manufacturing.

14 open like this View on SAM.gov Markdown

Response deadline

June 22, 2024 at 5:00 PM EDT

Closed 863 days ago. Posted May 22, 2024. Scheduled to archive July 7, 2024.

Get the next one like this from Centers for Disease Control and Prevention by email, the day it is posted.Find my opportunities

This one closed in 2024

14 like it are open now in in-vitro diagnostic substance manufacturing

All 14 open in in-vitro diagnostic substance manufacturing

Description

As published on SAM.gov.

The Influenza Division (ID) at the Centers for Disease Control and Prevention (CDC) is responsible for the detection and characterization of influenza viruses for the purposes of disease surveillance and vaccine strain selection. The ID is also responsible for influenza outbreak investigations, seasonal vaccine strain selections, and vaccine effectiveness studies.

There are often situations where the influenza laboratories are not capable of completing research projects due to a significant outbreak or emergence of a new virus subtype thus requiring a shift of testing priorities.

In these cases, Hemagglutinin Inhibition (HAI) assays, microneutralization (MN) assays, Sanger gene sequencing, and Reverse Transcription Polymerase Chain Reaction (RT-PCR) testing for vaccine strain selection and effectiveness studies need to be outsourced to publish study results in a timely manner. These activities in the contract will also serve as a vehicle for influenza surge testing when CDC laboratories are overwhelmed with other testing demands.

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. May 22, 2024

    Sources sought

    Due June 22, 2024 at 5:00 PM EDT. SAM.gov, notice 37649f3369f44352b9688d78b41b6e13

Points of contact